We are happy to announce the new International Law Talk Podcast episode on EU competition law developments in the pharmaceutical sector. And this one is twice as good! Not only are we discussing both…
On 25 March 2021, the European Court of Justice ("ECJ") dismissed all the appeals against the European Commission's decision to fine Lundbeck and several other companies for entering into anti…
What are commitments?
The recent effort by the Commission to settle the Aspen case suggests that commitment decisions are the preferred route to settle complex excessive pricing cases at EU-level…
Introduction
Servier v. Commission (Case T‑691/14) is the second decision of the General Court of the European Union on "pay-for-delay" patent settlements in the pharmaceutical industry,[1] following…
Introduction
On 27 September 2018, Turkish Competition Authority (“TCA”) published its decision[1] concerning the allegations that Roche Müstahzarları A.Ş. (“Roche”) had violated articles 4 and 6 of…
Throughout the last year, the topics of globalization in the markets and digitalization of economy were extensively discussed within the governmental authorities and business community in Russia. One…
Introduction
I recommend reading the UK Competition Appeal Tribunal’s (CAT) decision in Flynn/Pfizer vs UK Competition and Markets Authority (CMA) as both lawyers and economists can find a fair…
Summary
On 7 June 2018, the UK Competition Appeal Tribunal (CAT) held that the UK Competition and Markets Authority (CMA) misapplied the relevant legal test when finding that Pfizer and Flynn Pharma …
I. INTRODUCTION
In June 2015, Canada’s Competition Bureau released its updated draft of the Intellectual Property Enforcement Guidelines ("Draft IPEGs") for public review and consultation. The Draft…
